
Two moon missions touched down on the lunar surface. How they unfolded was a stark contrast
California-based asteroid mining company AstroForge shared on Thursday that its Odin spacecraft, which ventured to space a week and a half ago with Intuitive Machines' Athena lunar lander, met an untimely end.
The probe was heading for an asteroid to scout for the valuable resource platinum. But Odin's team said the vehicle is likely tumbling through space, with little hope of restoring communications.
Space is hard, and every bold mission adds lessons learned. This week, a tale of two lunar landers demonstrates why scientists and engineers always expect the unexpected in the saga of space exploration.
Defying gravity
On March 2, Firefly Aerospace's Blue Ghost lunar lander touched down on the moon, making it the second private sector company to execute the feat.
Photos showcasing the spacecraft's dramatic shadow on the lunar surface and its feet within moon dust confirmed the mission's success.
The Cedar Park, Texas-based company has since shared a video of the lander's nail-biting descent just north of the moon's equator.
Blue Ghost will spend the next week collecting samples, drilling into the subsurface and capturing high-definition imagery.
Lunar update
The Athena lander also made it to the moon, after descending near the lunar south pole on Thursday in hopes of conducting a water-finding mission.
Initially, Intuitive Machines was scrambling to determine the spacecraft's orientation. But images from Athena's suite of cameras helped confirm that the mission ended prematurely, with the lander lying on its side inside a crater.
The lander is 820 feet (250 meters) from the target landing site of Mons Mouton, a flat-topped mountain, the Houston-based company said.
Before powering down, Athena briefly operated and transmitted data, making it the 'southernmost lunar landing and surface operations ever achieved,' according to the company.
Back to the future
Meet the woolly mouse, genetically modified to have several woolly mammoth-like traits.
Engineered by Colossal Biosciences, the mice have curly whiskers and hair that grows three times longer than that of typical lab mice.
Colossal is attempting to resurrect mammoths and other extinct creatures, and the mice will enable its team to test links between specific genetic sequences and physical traits that enabled the giants to endure bitterly cold environments, according to the private Dallas company.
But the new study doesn't address whether the modified mice are actually tolerant of the cold, said Robin Lovell-Badge, head of the Stem Cell Biology and Developmental Genetics Laboratory at The Francis Crick Institute in London.
'As it is, we have some cute looking hairy mice, with no understanding of their physiology, behaviour, etc,' Lovell-Badge said via email.
Force of nature
The adventure of the world's biggest iceberg, known as A23a, may have come to an end after it spent five years wandering the Southern Ocean near Antarctica and, for a time, spinning around an undersea mountain.
The 'megaberg,' weighing 1.1 trillion tons (nearly 1 trillion metric tonnes) and slightly smaller than Rhode Island, ran aground on the island of South Georgia in the southern Atlantic Ocean.
'Nutrients stirred up by the grounding and from its melt may boost food availability for the whole regional ecosystem, including for charismatic penguins and seals,' said Andrew Meijers, an oceanographer at the British Antarctic Survey.
Now, scientists are trying to predict what will happen to A23a next, and what impact the iceberg will have if it splits into pieces.
A long time ago
Archaeologists have uncovered a cache of tools that ancient human ancestors crafted from elephant and hippopotamus bones 1.5 million years ago in Olduvai Gorge, known as the 'Cradle of Humankind,' in Tanzania.
The unexpected discovery makes these the oldest known bone tools by about 1 million years. The 27 bone fragments appear to have been systematically sharpened and shaped using stone.
Researchers believe our early human ancestors took the same sophisticated techniques they used to make stone tools and applied them to carefully selected limb bones from large animals.
The finding suggests that hominins were capable of critical thinking and innovative craftsmanship, but scientists are still trying to figure out who exactly made the tools.
Explorations
Let your curiosity ascend to new heights with these stories:
— For the second time this year, SpaceX's megarocket Starship exploded midflight during a test mission, disrupting air traffic and raining down flaming debris that was captured on video by onlookers in the Caribbean.
— The narwhal is often called the 'unicorn of the sea' because of its signature spiral tusk. Now, scientists have recorded the first video evidence revealing some surprising ways the Arctic whales use their tusks, including for playful behavior.
— The twin Voyager probes are each turning off a science instrument to conserve power and prevent both historic missions from ending within a few months.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California
Unlocking a new geography, making Neuraceq® available to more patients BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and distribution network for Neuraceq® (florbetaben F-18 injection) in Southern California. This expansion increases access to the broader Southern California area, including San Diego, extending availability of Neuraceq® to imaging centers, physicians, and patients with cognitive impairment. The first dose from a newly-equipped site in Los Angeles was provided on August 13, 2025. Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs. This expansion reflects LMI's ongoing commitment to advancing diagnostic access and improving outcomes for patients affected by Alzheimer's disease in California. "At LMI, we are focused on expanding geographical access to Neuraceq® for patients and physicians involved in the evaluation of Alzheimer's disease. As the adoption of anti-amyloid therapies continues to grow, the demand for reliable amyloid PET imaging is increasing in parallel. Launching Neuraceq® from Los Angeles is a key milestone in meeting this rising demand. It reflects our ongoing dedication to delivering timely, high-quality diagnostic solutions that align with the evolving needs of neurologists and patients," said Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC of LMI, a Lantheus company. About Neuraceq® (florbetaben 18F) Indications and Use NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products. CONTRAINDICATIONS: None WARNINGS AND PRECAUTIONS: Risk for Image Misinterpretation and other Errors: NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information] Radiation Risk: NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information]. ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%). For more information please visit: About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI), a Lantheus company, is dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland and Sweden, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit ContactsInvestor Relations: Mark KinarneyVice President, Investor Relations978-671-8842ir@ Media: Melissa DownsExecutive Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Life Molecular Imaging


Bloomberg
41 minutes ago
- Bloomberg
Longevity, Episode 2 04:58 Citi Investigates HR Complaints Against Andy Sieg 03:02 Howard Marks Says Stocks Seem Expensive to ‘Reality' 04:04 Ladenburg Thalmann Cuts NANO Nuclear to Sell 02:07 Tech Selloff the ‘Air Pocket of August': BNY's Levine Current Stream: U.S. BTV+ U.S. BTV+ U.S. BTV Europe BTV Asia BTV Australia BTV U.S. Live Event EMEA Live Event Asia Live Event Politics Live Event LIVE NOW 17:00 Bloomberg Balance of Power Bloomberg Balance of Power focuses on politics and policies on Capitol Hill, in President Trump's administration, the federal agencies and the courts. UP NEXT 18:00 Bloomberg Businessweek Daily See Full Schedule BTV Channel Finder Watch BTV in your area
SpaceX's Expensive Starship Explosions Are Starting to Add Up Plagued by failed test flights, Elon Musk's space company is under pressure to show progress in its massive rocket program. How long will investors keep the faith? Kiel Porter explains. (Source: Bloomberg)


Forbes
2 hours ago
- Forbes
Valley Fever Cases Surge To Record Levels In California
California is experiencing an unprecedented surge in Valley Fever cases, with health officials warning that 2025 could shatter previous records. As of the end of July, there were 6,761 confirmed cases, which means if this pace continues, the total 2025 numbers will likely exceed the 12,595 cases reported in 2024. This dramatic increase has prompted renewed public health warnings and highlights the urgent need for greater awareness of this potentially serious fungal infection. What Causes Valley Fever and How Is It Transmitted? Coccidioidomycosis, commonly known as Valley Fever, is caused by the fungus Coccidioides, which exists naturally in the soil of certain arid and semi-arid regions. The fungus thrives in areas with hot, dry summers and mild winters, making California, Arizona, and parts of Nevada, New Mexico, and northern Mexico prime endemic zones. The disease is transmitted through inhalation of fungal spores called arthroconidia. When soil containing the fungus is disturbed by activities such as construction, farming, excavation, or strong winds, the microscopic spores become airborne and can travel significant distances. People become infected by breathing in dust particles that are contaminated with the microscopic spores. Importantly, Valley Fever is not contagious between people or animals, meaning that an infected person can't transmit the disease to another individual or pet. The infection comes exclusively from environmental exposure to contaminated soil. Weather patterns and climate change have significantly impacted the risk of transmission. Periods of increased rainfall followed by dry conditions create an ideal setting for fungal growth and subsequent dispersion of the spores. This explains why California has seen such a dramatic increase in cases following recent wet winters, as the enhanced fungal growth eventually leads to greater spore production when conditions dry out. Often Silent, Yet Potentially Deadly Fortunately, nearly 60% of those who are infected with Coccidioides will not develop symptoms. However, in the remaining 40%, symptoms typically appear one to three weeks after exposure, though they can emerge anywhere from a few days to several months later. The disease presents in various forms, ranging from mild to severe. Most people with Valley Fever experience flu-like symptoms that can persist for weeks to months. Symptoms can include persistent fatigue, fever, dry cough, chest pain, shortness of breath, headaches, muscle aches, and joint pain. Many patients also develop a characteristic skin rash with red bumps or patches. The fatigue associated with Valley Fever can be particularly debilitating and may last for months even after other symptoms resolve. In approximately 5-10% of cases, the infection may progress to a chronic pulmonary form, causing persistent pneumonia-like symptoms, with the development of lung nodules that may be seen on chest X-ray. Less commonly, the infection can spread beyond the lungs to other parts of the body, including bones, joints, skin, and the central nervous system. This disseminated form is more serious and has a higher prevalence in pregnant women, people with a compromised immune system, and certain ethnic groups including African Americans, Filipinos, and Hispanics. Testing and Diagnosis Diagnosing Valley Fever can be challenging because its symptoms may closely resemble other respiratory illnesses. Many cases go undiagnosed or are misdiagnosed, leading to unnecessary antibiotic treatment and delayed prescription of antifungal medication. Several testing methods are available for diagnosis. Blood (i.e., serology) tests can detect antibodies that the immune system produces in response to the fungal infection. The fungus can also be grown in culture, but this can take several days, which may delay diagnosis and treatment. Molecular, or PCR, tests are available at select laboratories and can provide a rapid diagnosis from samples such as sputum, tissue or cerebrospinal fluid. Healthcare providers should consider Valley Fever testing for patients in endemic areas who present with persistent respiratory symptoms, especially during peak transmission seasons, which are usually late fall and early winter. Prevention Strategies While it's impossible to completely eliminate the risk of Valley Fever in endemic areas, several measures can significantly reduce the risk of becoming infected. The most effective prevention involves minimizing exposure to dust and disturbed soil. During high-risk periods, particularly windy days or dust storms, people should stay indoors with windows and doors closed and use air purification systems with high-efficiency filters. When outdoor activities are necessary, wearing a mask can provide protection against inhaling fungal spores. Those working in high-risk occupations, such as construction or agriculture, should use appropriate respiratory protection. Individuals at higher risk for severe disease, including pregnant women or those with a compromised immune system, should take extra precautions. This may include avoiding high-risk activities entirely and consulting with their healthcare provider about steps to stay safe and symptoms to watch out for. As Valley Fever cases continue to climb in California and other southwestern states, awareness and prevention become increasingly important. Understanding this fungal disease, recognizing its symptoms, and taking appropriate protective measures can help individuals and communities better navigate this growing public health challenge.